Journal of Antimicrobial Chemotherapy, Vol 39, 405-409, Copyright © 1997 by The British Society for Antimicrobial Chemotherapy
D Shonekan, S Handwerger and D Mildvan
The in-vitro activities of five investigational antibiotics, RP59500 (a
semisynthetic injectable streptogramin), CL 329,998 and CL 331,002 (two new
glycylcyclines), trovafloxacin (a naphthyridone), and clinafloxacin (a
dihalogenated quinolone), were examined and compared with those of
minocycline, teicoplanin and vancomycin against 190 clinical isolates of
Gram-positive cocci. The MICs for RP59500 against all isolates with the
exception of Enterococcus faecalis were low. RP59500 was bactericidal
against all except enterococcal isolates. CL 329,998 and CL 331,002 were
significantly more active than minocycline against oxacillin-resistant
Staphylococcus aureus (MIC90 0.25 versus 8 mg/L) and all enterococcal
isolates (MIC90 0.125 versus 16 mg/L). Clinafloxacin was the most active
agent against all staphylococcal isolates and was bactericidal.
Trovafloxacin showed good activity against oxacillin-susceptible
staphylococci and alpha-haemolytic streptococci (MIC90 < or = 0.125
mg/L). This study demonstrates the potential of the five investigational
antibiotics as therapeutic agents for infections caused by Gram-positive
cocci.
JOURNAL ARTICLE
Comparative in-vitro activities of RP59500 (quinupristin/dalfopristin), CL 329,998, CL 331,002, trovafloxacin, clinafloxacin, teicoplanin and vancomycin against Gram-positive bacteria
Division of Infectious Diseases, Beth Israel Medical Center, New York, NY 10003, USA.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  I. Chopra and M. Roberts Tetracycline Antibiotics: Mode of Action, Applications, Molecular Biology, and Epidemiology of Bacterial Resistance Microbiol. Mol. Biol. Rev., June 1, 2001; 65(2): 232 - 260. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Siami, N. Christou, I. Eiseman, K. J. Tack, and the Clinafloxacin Severe Skin And Soft Tissue Infe Clinafloxacin versus Piperacillin-Tazobactam in Treatment of Patients with Severe Skin and Soft Tissue Infections Antimicrob. Agents Chemother., February 1, 2001; 45(2): 525 - 531. [Abstract] [Full Text]
|
|
|
|
 |
|
 C. von Eiff and G. Peters Comparative in-vitro activities of moxifloxacin, trovafloxacin, quinupristin/dalfopristin and linezolid against staphylococci J. Antimicrob. Chemother., April 1, 1999; 43(4): 569 - 573. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Johnson, C. A. Taylor III, S. W. Zimmerman, W. E. Bridson, P. Chevalier, O. Pasquier, and R. I. Baybutt Pharmacokinetics of Quinupristin-Dalfopristin in Continuous Ambulatory Peritoneal Dialysis Patients Antimicrob. Agents Chemother., January 1, 1999; 43(1): 152 - 156. [Abstract] [Full Text]
|
|